JHM focuses on both consumer healthcare and therapeutic solutions. Our products include Recombinant Type I & Type III Human Collagen, Recombinant Type A Botulinum Toxin, Recombinant Human Growth Hormone, and Recombinant Long-Acting Growth Hormone.

Headquartered in Hangzhou, Zhejiang, China, JHM operates two GMP factories — one in Hangzhou and one in Tonghua. The Company excels in all phases of drug development and commercialization, from early-stage drug discovery and process development to clinical trials, manufacturing preparation, and product launch. This vertically integrated model provides a significant competitive advantage, allowing JHM to lead the industry's rapid progress and innovative transformation.

Since its establishment, JHM has successfully completed multiple rounds of financing, from Pre-A to B+, demonstrating the capital market's prominent recognition of the company's technological strength, product pipeline, and commercial prospects.

In 2024, JHM was recognized as a “Specialized and Sophisticated SME in Zhejiang Province.”